18-Month Retrospective Claims Analysis Study Information on Ruxolitinib

Patients Express Concerns Over Costs, Risks of Gene Therapies for Sickle Cell Disease

Stethoscope sitting on money | Image credit: Valeri Luzina - stock.adobe.com

A Single CRISPR Treatment Could Replace a Lifetime of Daily Treatment in Hereditary Angioedema

Research at the annual meeting of the American Society of Hematology evaluated patient and caregiver perspectives on gene therapies for sickle cell disease, which offer great potential but have had slow uptake.

A gene being edited | Image credit: natali_mis - stock.adobe.com

New Chronic GVHD Treatments Show Promise, but Long-Term Outcomes Are Not Well Understood

In a phase 2 trial, a gene therapy reduced angioedema attacks, which could significantly change the quality of life for patients with hereditary angioedema.

GVHD wood blocks with pills | Image credit: Dzmitry - stock.adobe.com

GVHD Cannot Be Wholly Prevented, so Effective Treatments Are Needed, Says Dr. Daniel Wolff

A single-center retrospective study found the approval and use of new agents to treat chronic graft-versus-host disease (GVHD) is associated with quality-of-life improvements.

Wooden blocks spelling GVHD | Image credit: Stanislau - adobe.stock.com

Evolving Role of Statins in Managing CV Risk in HIV | ID Week 2024

Chronic and acute graft-versus-host disease are managed differently, affect different organs, and impact patients in different ways.

Screenshot of an interview with Michelle Cespedes, M.D.

Peter Wehrwein, Managing Editor;Laura Joszt, MA

Exploring Real-World Atopic Dermatitis Treatment Patterns | Written Recap

Statins have had an evolving role in the management of cardiovascular risk in people living with HIV, explained Michelle Cespedes, M.D., M.S., professor of medicine, Icahn School of Medicine at Mount Sinai and Mount Sinai Health System.

Related Content

Peter Wehrwein, Managing Editor

Patients Express Concerns Over Costs, Risks of Gene Therapies for Sickle Cell Disease

A Single CRISPR Treatment Could Replace a Lifetime of Daily Treatment in Hereditary Angioedema

New Chronic GVHD Treatments Show Promise, but Long-Term Outcomes Are Not Well Understood

In a phase 2 trial, a gene therapy reduced angioedema attacks, which could significantly change the quality of life for patients with hereditary angioedema.

GVHD Cannot Be Wholly Prevented, so Effective Treatments Are Needed, Says Dr. Daniel Wolff

A single-center retrospective study found the approval and use of new agents to treat chronic graft-versus-host disease (GVHD) is associated with quality-of-life improvements.